ArticleClinical rheumatology2021
Is there a potential dual effect of denosumab for treatment of osteoporosis and sarcopenia?
Article in Clinical rheumatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07271771 (The Effect of Denosumab on Muscle and Strength and Insulin Sensitivity), which is not on this map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Effect of Denosumab on Muscle and Strength and Insulin Sensitivity
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- Beyond bone effects: the role of denosumab in muscle Health - A systematic review.Aging clinical and experimental research · 2026Pooled it
- Anti-resorptive and anabolic therapies improve Falls Risk Assessment Score (FRAS) in postmenopausal women with type 2 diabetes mellitus.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2025Trial
- Denosumab for Primary Osteoporosis and Its Impact on Sarcopenia in the Chinese Population: Insights from Clinical Evidence and RANKL Pathway Mendelian Randomization.Clinical interventions in aging · 2025Trial
- Does Zoledronic Acid Improve Appendicular Lean Mass in Older Women with Osteoporosis? A Sub-Analysis of a Randomized Clinical Trial.The Journal of frailty & aging · 2022Trial
- Denosumab therapy is associated with a reduced risk of clinically diagnosed rotator cuff tears: a multi-institutional real-world cohort study.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026Article
- Comparison of Denosumab and Bisphosphonates for Sarcopenia in Postmenopausal Osteoporosis.Journal of clinical medicine · 2026Article
- Impact of Denosumab Adherence on Renal Function and Mortality Rates in Type 2 Diabetes Patients With Osteoporosis.The Kaohsiung journal of medical sciences · 2026Article
- Article
- Sarcopenia and Muscle Aging: Updated Insights into Molecular Mechanisms and Translational Therapeutics.Endocrinology and metabolism (Seoul, Korea) · 2026Review
- Immunometabolic mechanisms of osteosarcopenic obesity: chronic inflammation, trained immunity, and systemic immune dysregulation.Frontiers in immunology · 2026Review
- Article
- Rethinking Osteoporosis Drugs: Can We Simultaneously Address Sarcopenia?International journal of molecular sciences · 2025Review
- Osteosarcopenia and geriatric hip fractures: Current concepts.World journal of orthopedics · 2025Review
- Beyond Bone Remodeling: Denosumab's Multisystemic Benefits in Musculoskeletal Health, Metabolism, and Age-Related Diseases-A Narrative Review.Biomedicines · 2025Review
- Extra-osseous Roles of the RANK-RANKL-OPG Axis with a Focus on Skeletal Muscle.Current osteoporosis reports · 2024Review
- Effect of zoledronic acid on muscle metabolism in mice with osteoporosis combined with sarcopenia.BMC musculoskeletal disorders · 2024Article
- Association of chronic liver disease with bone diseases and muscle weakness.Journal of bone and mineral metabolism · 2024Review
- Advances in sarcopenia: mechanisms, therapeutic targets, and intervention strategies.Archives of pharmacal research · 2024Review
- Advances in the Study of Denosumab Treatment for Osteoporosis and Sarcopenia in the Chinese Middle-Aged and Elderly Population.International journal of general medicine · 2024Review
- Drug adherence and treatment duration for denosumab and mortality risk among hip fracture patients.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 7 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe prevalence of sarcopenia with osteoporosis results in a higher risk of falling and fractures. It was noted that patients who had completed their planned 5-year denosumab therapy course as treatment for these conditions started to sustain falls. PURPOSE: To assess (a) whether denosumab has a unique dual effect on both bone and muscle in comparison to other anti-resorptive agents and (b) its effectiveness in the follow-up period post-treatment completion compared to other anti-resorptive agents.
methodOne hundred thirty-five patients diagnosed to have postmenopausal/senile osteoporosis and who were prescribed denosumab were compared to a control group of 272 patients stratified into 2 subgroups - 136 prescribed alendronate and 136 prescribed zoledronate. All patients were assessed for: BMD (DXA), falls risk (FRAS), fracture risk (FRAX), and sarcopenia measures. All were re-assessed after 5 years of denosumab/alendronate therapy and 3 years of zoledronate and 1 year after stopping the osteoporosis therapy.
resultsNo significant baseline demographic differences between the 3 groups. On completion of the 5-year denosumab therapy, there was significant decrease in falls risk (P = 0.001) and significant improvements in all sarcopenia measures (P = 0.01). One-year post-discontinuation of denosumab, a significant worsening of both falls risk and sarcopenia measures (P = 0.01) noticed.
conclusionDenosumab displayed positive impact and significant improvements in BMD and sarcopenia measures. It also enhanced multidirectional agility as depicted by Timed Up and Go (TUG). Collectively, this would explain the reduction of falls risk which got worse on stopping the medication. Key points • The coexistence of osteoporosis and sarcopenia has been recently considered in some groups as a syndrome termed 'osteosarcopenia'. • Bone and muscle closely interact with each other not only anatomically, but also at the chemical and metabolic levels. • Denosumab displayed positive impact and significant improvements in all sarcopenia measures, and enhanced multidirectional agility with consequent reduction in falls risk. • Denosumab can be considered as a first osteoporosis therapeutic option in this group of patients presenting with osteosarcopenia manifestations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.